← CSPC Innovation Pharmaceutical overview

CSPC Innovation Pharmaceutical vs Danone SA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest16 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Danone SA (BN.PA)

Q3 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

July 202622 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.

Latest22 Jun – 4 Sep 2026

▲4

Danone buys growth brands, beats Q2, strengthens patent

Acquires MADE Group and full Australian dairy JV Danone is buying Australia's MADE Group (high-protein drinks, gut-health yoghurts) and the rest of its Australian dairy joint venture. Both add fast-growing health products and are expected to lift profit margins and earnings per share from the first year, supporting the shares.
A concrete deal that adds growth and profit, directly supporting the stock.
Q2 sales beat forecasts, full-year outlook kept Danone's second-quarter sales grew 4.2% versus the 3.7% expected, with specialized nutrition and water (helped by a heatwave) both strong. First-half operating profit and margin came in slightly ahead, and the company kept its full-year growth target, reassuring investors.
The quarter's results beat expectations and confirm the company is on track.
Completes Huel acquisition, expands functional nutrition Danone finished buying Huel, the meal-shake and nutrition brand, adding its direct-to-consumer reach to Danone's global scale. Huel joins the accounts from September 1, 2026, broadening Danone's functional nutrition business and its growth options.
A completed deal that expands a fast-growing part of the business.
New U.S. patent strengthens Akkermansia gut-health IP Danone's subsidiary won a new U.S. patent and favorable rulings protecting its Akkermansia weight-loss ingredient, though appeals continue. Stronger legal protection supports its launch of Akkermansia products in the U.S., Europe and Asia, a potential new sales driver.
Protects a promising new product line, a real positive for future sales.